Amro Aboukameel
Research Subjects
Research Interests
Amro Aboukameel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Asfar Sohail Azmi
Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
4 shared publications - Hafiz Uddin
Wayne State University 1 Detroit, MI
4 shared publications - Husain Yar Khan
Wayne State University 1 Detroit, MI
4 shared publications - Ramzi M. Mohammad
Wayne State University School of Medicine, Karmanos Cancer Institute 5 Detroit, Michigan
4 shared publications - Sahar F. Bannoura
Wayne State University 1 Detroit, MI
4 shared publications - Anthony F. Shields
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Proliferating Cell Nuclear Antigen as New Therapeutic Target in Multiple Myeloma
Multiple myeloma (MM), the second most common hematologic malignancy, remains incurable despite major therapeutic advances, highlighting an urgent need for novel therapeutic strategies. PCNA is involved in DNA replication and repair, chromatin remodeling, and cell-cycle progression, and increased PCNA expression has been associated with aggressive MM phenotypes and poor clinical outcomes. Cancer cells express a post-translationally modified cancer-associated isoform of PCNA (caPCNA), potentially providing a selective therapeutic target. We evaluated the anti-myeloma activity of the novel caPCNA inhibitor AOH1996 alone and in combination with established anti-myeloma agents in vitro, in vivo, and ex vivo. AOH1996 inhibited growth of multiple MM cell lines in a dose-dependent manner, induced G2-phase accumulation and apoptosis, and reduced sphere formation and colony formation capacity. Combination treatment with bortezomib, venetoclax, melphalan, or cyclophosphamide enhanced anti-myeloma activity relative to single-agent treatment. AOH1996 treatment down-regulated the expression of multiple tumor-associated proteins and inflammatory and pro-survival cytokines. miRNA analysis demonstrated suppression of several oncogenic miRNAs along with upregulation of tumor-suppressive miRNA miR-145. Forced expression of miR-145 inhibited MM cell growth and enhanced sensitivity to AOH1996, implicating miR-145 as a mechanistic mediator of PCNA inhibition’s anti-tumor effects. In xenograft models, AOH1996 significantly enhanced the anti-tumor activity of bortezomib and venetoclax without apparent toxicity. Ex vivo studies demonstrated selective activity against primary MM cells and CD138+ plasma cells with minimal effects on normal PBMCs. Collectively, these findings support caPCNA as a promising therapeutic target in MM and provide strong preclinical rationale for further clinical investigation of AOH1996-based therapeutic strategies.
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Open AccessProliferating Cell Nuclear Antigen as New Therapeutic Target in Multiple Myeloma
Multiple myeloma (MM), the second most common hematologic malignancy, remains incurable despite major therapeutic advances, highlighting an urgent need for novel therapeutic strategies. PCNA is involved in DNA replication and repair, chromatin remodeling, and cell-cycle progression, and increased PCNA expression has been associated with aggressive MM phenotypes and poor clinical outcomes. Cancer cells express a post-translationally modified cancer-associated isoform of PCNA (caPCNA), potentially providing a selective therapeutic target. We evaluated the anti-myeloma activity of the novel caPCNA inhibitor AOH1996 alone and in combination with established anti-myeloma agents in vitro, in vivo, and ex vivo. AOH1996 inhibited growth of multiple MM cell lines in a dose-dependent manner, induced G2-phase accumulation and apoptosis, and reduced sphere formation and colony formation capacity. Combination treatment with bortezomib, venetoclax, melphalan, or cyclophosphamide enhanced anti-myeloma activity relative to single-agent treatment. AOH1996 treatment down-regulated the expression of multiple tumor-associated proteins and inflammatory and pro-survival cytokines. miRNA analysis demonstrated suppression of several oncogenic miRNAs along with upregulation of tumor-suppressive miRNA miR-145. Forced expression of miR-145 inhibited MM cell growth and enhanced sensitivity to AOH1996, implicating miR-145 as a mechanistic mediator of PCNA inhibition’s anti-tumor effects. In xenograft models, AOH1996 significantly enhanced the anti-tumor activity of bortezomib and venetoclax without apparent toxicity. Ex vivo studies demonstrated selective activity against primary MM cells and CD138+ plasma cells with minimal effects on normal PBMCs. Collectively, these findings support caPCNA as a promising therapeutic target in MM and provide strong preclinical rationale for further clinical investigation of AOH1996-based therapeutic strategies.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.
- Open Access
- 13 September 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12) , 1422-1433
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.
- 13 September 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12) , 1422-1433
Open AccessAnticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). PAK4 is a hub molecule that links several major signaling pathways and is known for its tumorigenic role in mutant Ras–driven cancers. We found that cancer cells resistant to KRASG12C inhibitor were sensitive to KPT9274-induced growth inhibition. Furthermore, KPT9274 synergized with sotorasib and adagrasib to inhibit the growth of KRASG12C-mutant cancer cells and reduce their clonogenic potential. Mechanistically, this combination suppressed cell growth signaling and downregulated cell-cycle markers. In a PDAC cell line–derived xenograft (CDX) model, the combination of a suboptimal dose of KPT9274 with sotorasib significantly reduced the tumor burden (P= 0.002). Similarly, potent antitumor efficacy was observed in an NSCLC CDX model, in which KPT9274, given as maintenance therapy, prevented tumor relapse following the discontinuation of sotorasib treatment (P= 0.0001). Moreover, the combination of KPT9274 and sotorasib enhances survival. In conclusion, this is the first study to demonstrate that KRASG12C inhibitors can synergize with the PAK4 inhibitor KPT9274 and combining KRASG12C inhibitors with KPT9274 can lead to remarkably enhanced antitumor activity and survival benefits, providing a novel combination therapy for patients with cancer who do not respond or develop resistance to KRASG12C inhibitor treatment.